ADORA2A and non-small cell lung carcinoma: Compound 1 (as a selective A2AR agonist and a PDE10A inhibitor) exhibited increased potency for both cAMP accumulation and anti-proliferative actions, which increased in tandem with the combined target expression (A2AR and PDE10A) across the NSCLC cell lines, from LK-2-H520-H1792-H1563.